Malignant glial tumors (anaplastic astrocytomas and glioblastomas multiforme) arise mostly either from the progression of low grade precursor lesions or rapidly in a de novo fashion and contain distinct genetic alterations. There is, however, a third subset of malignant gliomas in which genetic lesions remain to be identi®ed. Following surgical resection, all gliomas appear to have an inherent tendency to recur. Comparative molecular analysis of ten primary malignant gliomas (three anaplastic astrocytomas and seven glioblastomas multiforme) with their recurrences identi®ed two distinct subgroups of recurrent tumors. In one group, primary tumors harbored genetic aberrations frequently associated with linear progression or de novo formation pathways of glial tumorigenesis and maintained their genetic pro®les upon recurrence. In the other subset with no detectable known genetic mutations at ®rst presentation, the recurrent tumors sustained speci®c abnormalities associated with pathways of linear progression or de novo formation. These included loss of genes on chromosomes 17 and 10, mutations in the p53 gene, homozygous deletion of the DMBTA1 and p16 and/ or p15 genes and ampli®cation and/or overexpression of CDK4 and alpha form of the PDGF receptor. Recurrent tumors from both groups also displayed an abnormal expression pro®le of the metalloproteinase, gel A, and its inhibitor, TIMP-2, consistent with their highly invasive behavior. Delineation of the molecular dierences between malignant glioblastomas and their subsequent recurrences may have important implications for the development of rational clinical approaches for this neoplasm that remains refractory to existing therapeutic modalities.
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Keywords: malignant gliomas; recurrence; genetic pro®les Glioblastomas are considered to be among the most malignant human cancers and are composed of multiple cell types displaying a wide spectrum of heterogeneity in terms of morphology, biological aggressiveness, invasive potential, and radiation sensitivity. Despite the availability of sophisticated diagnostic and surgical procedures and considerable advances in various therapeutic modalities, the prognosis for glioblastomas has not improved. Following a short period of remission the tumors almost always recur and the patients succumb to the progressive disease. The treatment modalities at recurrence include reoperation, targeted radiation, and/or experimental therapies, all of which have not made a noticeable impact on the clinical outcome. An understanding of the molecular mechanisms involved in the formation and progression of glioblastomas and their subsequent recurrences is crucial to the development of rational therapeutic approaches.
Despite the phenotypic and biologic heterogeneity, most glioblastomas appear to be monoclonal neoplasms resulting from the genetic alterations that accumulate during the clonal expansion of a transformed astrocyte (Berkman et al., 1992; Morse et al., 1994) . One or more of these multiple genetic alterations, sometimes in speci®c combinations and at speci®c stages, occur in glial tumorigenesis. Attempts have been made to distinguish between distinct subtypes of glioblastomas based upon their molecular pro®les (von Deimling et al., 1993 ). It appears that glioblastomas evolving through the linear progression pathway possess, as primary defects, chromosome 17p/ p53 abnormalities and platelet derived growth factor and/or receptor (PDGFR) overexpression. During the course of progression these low grade tumors sustain combinations of sequence losses on chromosomes 1, 9, 10, 13, 19 and 22 Louis, 1997) . Glioblastomas arising de novo or through rapid dedierentiation, on the other hand, have primarily epidermal growth factor receptor (EGFR) activation and chromosome 10 loss (von Deimling et al., 1993; Louis and Gusella, 1995; Louis, 1997) . There is, however, a subset of glioblastomas that do not contain any of the abnormalities characteristic of either the linear progression or the de novo formation pathway and the genetic lesions of which have yet to be identi®ed Louis, 1997) .
The nature of genetic abnormalities that accompany when a low grade astrocytoma recurs as anaplastic astrocytoma or glioblastoma multiforme has been studied. The p53 gene is implicated in the progression of astrocytomas. Loss of heterozygosity of chromosome 17 and mutations in the gene frequently occur in low grade astrocytomas and identical p53 mutations can be detected when these low grade tumors progress to anaplastic astrocytomas and glioblastomas (Hayashi et al., 1991; Sidransky et al., 1992; Reifenberger et al., 1996) . Similarly, increased expresion of PDGFRa is likely to be an initial event in the formation of gliomas with upregulation of the receptor expression in high malignancy grade gliomas (Hermanson et al., 1996) .
It is not known, on the other hand, what molecular dierences, if any, exist between the high grade gliomas, i.e. anaplastic astrocytomas and glioblastomas multiforme, at initial presentation and their subsequent recurrences which are clinically indistinguishable from primary tumors. An accurate prediction of tumor behavior has been dicult on the basis of studies comparing cytogenetic abnormalities, biologic properties, and various growth characteristics of glioblastomas at presentation and upon recurrence (Pruchon et al., 1994; Ritter et al., 1994; Rajan et al., 1994) . We have previously reported that a subset of recurrent glioblastomas sustained homozygous deletions of p16, alone or with the neighboring gene p15, or acquired ampli®ed copy number of CDK4 genes that play a crucial role in cell cycle progression (Saxena et al., 1996) . In this study, we compared molecular genetic pro®les of ten high grade gliomas (seven glioblastomas multiforme and three anaplastic astrocytomas) and their subsequent recurrences for multiple genetic aberrations that are commonly associated with glial tumorigenesis.
The molecular parameters analysed on matched pairs of primary and malignant glioblastomas included (1) multiple restriction fragment length polymorphism (RFLP) markers on chromosome 17p (D17S34, D17S28, D17S5, D17S31, p53, and D17S71) spanning the p53 locus as well as the region where another putative tumor suppressor gene implicated in glioblastoma resides , (2) multiple RFLP (D10S1, D10S4, D10S25, D10S19 and D10S28) and microsatellite markers (D10S215, D10S541, AFM086, AFM280, D10S169, D10S209, D10S216, D10S217) on chromosome 10, spanning the recently cloned PTEN/ MMAC1 (Li et al., 1997; Steck et al., 1997) and DMBT1 genes (Mollenhauer et al., 1997) , (3) sequencing of the exons 5 ± 9 of the p53 gene, (4) SSCP analysis of all nine exons of the PTEN/MMAC1 gene, (5) duplex PCR to determine the homozygous deletion of the DMBT1 gene, (6) ampli®cation and/or overexpression of the EGFR and PDGFRa genes, and (7) expression of gelatinase A (gelA) and its inhibitor, tissue inhibitor of metalloproteinase-2 (TIMP-2) by Northern blotting.
Based upon the results of the genetic loci examined, two distinct groups of recurrent malignant gliomas could be distinguished, which either maintained the genetic pro®les of the primary tumors or acquired new genetic lesions during their recurrent expansion ( Table  1) . Five of the ten primary tumors in Group A carried at least one or more mutations, often detected in glial tumors. In the primary tumor of patient 10, allelic deletions targeting the region 17p13.3 distal to the p53 gene, a C to G transversion of codon 151 in exon 5 in one copy of the p53 gene, and loss of heterozygosity on chromosome 10 were detected. Our previous results demonstrated homozygous deletion of p16 and p15 genes on chromosome 9p in the primary tumor of patient 10 (Saxena et al., 1996) . The tumor from patient 36 suered allelic losses on chromosome 10 and E/E OE/OE P, primary; R, recurrent; R1, ®rst recurrence; R2, second recurrence. AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; histopathological diagnosis of the tumors was according to the WHO classi®cation (Kleiheus et al., 1993) . A, ampli®ed; E, expressed; LOH, loss of heterozygosity; ND, not done; NE, not expressed; NM, not mutated; OE, overexpressed; S, single copy. +, retention of heterozygosity; 7, loss of heterozygosity. *, Although LOH was not seen with chromosome 10 markers used in this study, recurrent tumors from patients 53 and 102 had homozygous deletions of the DMBT1 gene (see Figure 1b) . Results from patients 10, 16, and 36 on p53 mutations and ampli®cation/ overexpression of PDGFR and EGFR were partially presented previously (Fleming et al., 1992; Saxena et al., 1992) without comparing the primary/recurrent tumor pairs. Data in the p16/p15 and CDK4 columns are from Saxena et al. (1996) Figure 1 Dierential molecular genetic pro®les of primary high malignancy grade glial tumors and the subsequent recurrences. L, lymphocyte DNA; P, primary tumor DNA; R, recurrent tumor DNA. DNAs were extracted from the central parts of tumor specimens where contamination from normal cells was estimated to be less than 20%. In cases with unequal allele intensities in the lymphocyte DNA, autoradiograms were quantitated using microtek scanmaker 3 and the kodak digital science 1D image analysis software program. The relative integrated density value of the lower intensity allele to the higher intensity allele in lymphocyte DNA was arbitrarily set at 100% and a value of 50% or less in tumor DNA compared to lymphocyte DNA was considered as allele loss. (a) Patient 1: one normal and one mutated copy of the p53 gene with a G to A transition in codon 173 of exon 5 and allelic deletion at D10S28 in recurrent tumor DNA (integrated densities: L, 100%; P, 67%; R, 33%). Patient 16: allelic deletion at D17S28 marker, a T to C transition in codon 145 of exon 5 of the p53 gene and ampli®cation of the alpha form of the PDGFR in recurrent tumor DNA. The same Taq 1 digested blot stripped and probed with D10S4 marker is shown as a control for DNA loading. (b) Patient 53: homozygous deletion of the marker g14ext located within the DMBT1 gene ampli®ed in a duplex PCR reaction using the c12 marker on chromosome 8 as an internal control as described (Mollenhauer et al., 1997) . Patient 102: allelic deletion at D17S5 (integrated densities: L, 100%; P, 115%; R, 49%) and homozygous deletion at markers 36k and g14ext located within the DMBT1 gene in the recurrent tumor DNA. Patient 137: allelic deletion at D17S5 in the recurrent tumor DNA. The residual bands at dierent loci in the recurrent tumor DNAs from patients 1 (D10S28), 16 (D17S28), 102 (D17S5, 36k, and g14ext), and 137 (D17S5) indicate contamination to a varying degree with normal cells also contained ampli®ed copies of the EGFR gene which was overexpressed. The only abnormality detected in the glioblastoma from patient 46 was an A to G transition in codon 234 of exon 7 in one copy of the p53 gene, whereas the other copy was normal. The tumors from patients 113 and 134 sustained homozygous deletions of p16 and p15 genes (Saxena et al., 1996) . In addition, the tumor from patient 113 overexpressed the a and b forms of PDGFR, whereas the tumor from patient 134 suered allelic losses at all informative markers on chromosome 17p but had no mutation in exons 5 ± 9 of the remaining copy of the p53 gene. Upon recurrence all ®ve tumors maintained identical genetic pro®les of mutations. It is, however, entirely possible that yet to be identi®ed mutations were acquired by this subset of recurrent tumors.
The four primary tumors in Group B, no. 1, 16, 53 and 137, did not contain any of the genetic lesions examined in this study and thus belonged to the group of glioblastomas in which genetic lesions remain to be identi®ed. Upon recurrence, these four tumors and the primary tumor from patient 102 with homozygous deletions of the p16 and p15 genes on chromosome 9p (Saxena et al., 1996) displayed dierential pro®les containing multiple genetic abnormalities (Table 1, Figure 1 ). Although the recurrent tumor from patient 1 retained heterozygosity at all informative loci on 17p, one copy of the p53 gene contained a G to A transition in codon 173 of exon 5 and also suered loss of heterozygosity on chromosome 10 as detected by the D10S28 marker. The recurrent tumor from patient 16 suered allelic losses at multiple 17p loci together with a T to C transition in codon 145 of exon 5 of the remaining copy of the p53 gene and also contained high copy number of the PDGFRa gene (Figure 1a) . Overexpression of both a and b forms of PDGFR at the protein level (Fleming et al., 1992) and amplification of the CDK4 gene (Saxena et al., 1996) were also detected in the recurrent tumor of patient 16. Figure 1b demonstrates homozygous deletion of the DMBT1 gene, located on 10q25.3-26.1 (Mollenhauer et al., 1997) , in the recurrent tumor of patient 53. In the duplex PCR, the marker g14ext, located within the DMBT1 gene, was ampli®ed in the lymphocyte and the primary tumor, but was absent from the recurrent tumor. Ampli®cation of the c12 marker present on chromosome 8 and used as an internal control occurred in all three DNAs derived from lymphocytes and primary and recurrent tumors of patient 53. Three other markers, 74k, 36k and 101n mapped within the DMBT1 gene (Mollenhauer et al., 1997) , were also homozygously deleted in the recurrent tumor DNA of patient 53 (data not shown). Deletion of sequences at multiple 17p loci were detected in the recurrent tumors of patients 102 and 137, examples of which are displayed in Figure 1b ; none of the 17p markers were deleted in the respective primary tumors. Furthermore, the DMBT1 gene was homozygously deleted in the recurrent tumor of patient 102 (Figure 1b ) and the CDK4 gene was ampli®ed in the recurrent tumor of patient 137 (Saxena et al., 1996) .
We have previously reported that malignant gliomas frequently sustain a combination of allelic losses on chromosome 17p and mutations in the p53 gene . In the panel of matched pairs of primary and recurrent malignant tumors analysed in this study, three tumors in Group A and four tumors in Group B suered allelic deletions on chromosome 17p and/or mutations in the p53 gene. The four codons, 145, 151, 173 and 234, mutated in the primary and/or recurrent tumors, reside in the DNA-binding core domain of the protein (Cho et al., 1994) and are mutated in multiple human cancers (Universal Mutation p53 Database, http://www.umd.necker.fr:2001/). Although none of these residues are involved in the direct interaction of p53 with DNA, they may be important for the conformational stability of the p53 protein (Cho et al., 1994) . In particular, Pro 151, a de novo germline mutation of which has been reported (Gutierrez et al., 1994) , appears to be important for the structure of the short loops at the end of the b sandwich (Cho et al., 1994) and was detected in a yeast assay for dominant negative p53 mutations (Brachmann et al., 1996) . Decreased DNA binding has been reported for the p53 protein with mutations in codons 151 and 234 (Rolley et al., 1995; Kern et al., 1991) . Mutations in all four codons were detected in a study analysing a large number of breast tumors and the patient with P151A mutation had a short disease free survival and distant metastasis (Berns et al., 1998) . Furthermore, mutation in codon 151 without the accompanying loss of the wild type allele has recently been reported in a larynx carcinoma (Eber et al., 1998) . The functional signi®cance of speci®c p53 mutations in the recurrence of glioblastomas needs to be analysed in the context of genetic lesions in other signaling pathways involved in the genesis and progression of these tumors.
The tumors were also analysed for possible mutations in the tumor suppressor gene located on chromosome 10q23.3. SSCP analysis of all nine exons of the PTEN/ MMAC1 gene carried out on six pairs of primary/ recurrent pairs (patients 36 and 113 from group A and patients 16, 53, 102 and 137 from group B) did not show any alterations under the conditions used. We also failed to detect gene losses in all ten recurrent tumors with at least 2 ± 4 markers each on chromosomes 1, 2, 4, 6, 7, 8, 16 and 19 suggesting that radiation-induced nonrandom losses were uncommon. The markers on chromosome 19q covered the region where the putative tumor suppressor locus for glial tumors is mapped (Yong et al., 1995; Rosenberg et al., 1996) .
Several studies have reported the overexpression of a variety of proteinases in malignant gliomas (Yamamoto et al., 1994 (Yamamoto et al., , 1996 Nakagawa et al., 1994; Mikkelsen et al., 1995) . It has been shown that glioblastomas have an abnormal expression pro®le of gel A and its inhibitor, TIMP-2 (Saxena et al., 1995) , which has activities independent of its ability to inhibit metalloproteinases (Stetler-Stevenson et al., 1992; Nemeth and Goolsby, 1993) . The data from the comparison of six of the ten pairs of primary malignant gliomas and their corresponding recurrences are presented in Table 1 . Recurrent tumors from both Groups A and B expressed increased levels of gel A as well as TIMP-2 compard with their primary counterparts, examples of which are shown in Figure 2 . Gelatinase A was not detectable in the primary tumor of patient 1, but was expressed in the primary tumor of patient 137; both tumors expressed detectable levels of TIMP-2. Upon recurrence, tumors from both patients contained increased levels of gel A as well as TIMP-2. Glioblastoma multiforme is characterized by both genetic and phenotypic heterogeneity. This`end point' of glial neoplasms is unique in the sense that it is arrived at by the progression of multiple low-grade tumors (astrocytomas, oligodendrogliomas and oligoastrocytomas) and by multiple independent mechanisms (linear progression, de novo formation and unknown mechanism). It is possible that multiple genetic pathways of glioblastomas have distinctive biological and/or clinical signi®cance which have implications for therapeutic modalities both for tumors at initial presentation and for their subsequent recurrences. It is therefore important to analyse molecular pro®les of these tumors both at ®rst presentation and at subsequent recurrence. Such a comparative analysis of matched pairs of high malignancy grade primary/recurrent lesions carried out in this study has discerned two distinct subgroups among the recurring tumors as outlined in Figure 3 .
The panel of high malignancy grade glial tumors at ®rst presentation included both primary and secondary glioblastomas, as de®ned by their distinct molecular features, as well as tumors arising by unknown genetic mechanisms. These tumors were tentatively categorized into two groups based upon the comparative genetic pro®les of the corresponding recurrent tumors. The ®rst subgroup of tumors consisting of primary and secondary glioblastomas, arising via de novo formation and linear progression pathways respectively, did not acquire additional genetic lesions during the recurrent expansion, albeit an abnormal expression pro®le of gel A and TIMP-2. The time interval for recurrence of this group of gliomas varied between 8 ± 16 months. The second subset mostly included primary malignant glial tumors, which had no identi®able genetic abnormalities frequently implicated in the genesis of glioblastomas but had nevertheless realized its maximum malignant potential from the clinical standpoint. The primary glioblastoma from patient 102 with homozygous deletions of p16 and p15 genes (Saxena et al., 1996) was also included in this group based upon the acquisition of multiple abnormalities by all ®ve tumors during their recurrent growth the time interval for which varied between 5 ± 25 months. These genetic lesions included loss of genes on the short arm of chromosome 17 and mutations in the p53 gene (1R, 16R, 102R and 137R), ampli®cation/overexpression of PDGFR (16R), loss of genes on chromosome 10 (1R, 53R, and 102R) and/or abnormalities in p16, p15, and CDK4 genes (1R, 16R, 53R, 137R). One common abnormality between both subgroups of recurrent tumors, however, was increased expression of gel A and Timp-2 as compard with the primary tumors. An abnormal expression pro®le of metalloproteinases and their inhibitors is believed to contribute to the invasive Figure 3 Two subsets of recurrent malignant glial tumors distinguished by molecular pathways. PAA, primary anaplastic astrocytomas; RAA, recurrent anaplastic astrocytomas; PGBM, primary glioblastomas multiforme; RGBM, recurrent glioblastomas multiforme. Solid lines indicate anaplastic astrocytomas/glioblastomas multiforme arising via distinct molecular mechanisms (von Deimling et al., 1993; Louis and Gusella, 1995) . Broken lines indicate two subsets of recurrent anaplastic astrocytomas/ glioblastomas multiforme that either maintain the genetic pro®les present in the primary tumors or acquire genetic lesions associated with the linear progression and de novo formation pathways. Both subsets of recurrent tumors express high levels of gel A and TIMP-2 and angiogenic phenotype of various tumors. Elevated levels of gel A and TIMP-2 are consistent with the more aggressive nature of the recurrent glial neoplasms.
Because of the relatively small number of the primary/recurrent pairs of tumors employed in the present analysis, it is not possible to assess the biological and clinical signi®cance of the two subgroups of recurrent glial tumors. It is important to examine if a possible correlation exists between the two distinct groups of recurrent gliomas and the diseasefree and/or overall survival of the patients. Molecular analysis of an expanded panel of matched pairs of high malignancy grade primary and recurrent glioblastomas should provide a better insight into the poorly de®ned aggressive phenotype of recurrent glioblastomas. Also, an understanding of the molecular dierences between high malignancy grade glial tumors and their subsequent recurrences may be helpful in developing targeted multimodality therapies that have a better clinical outcome.
